|
Abstract
2005, Vol. 76, No. 11, Pages 1927-1933
, DOI 10.1902/jop.2005.76.11.1927
(doi:10.1902/jop.2005.76.11.1927)
Systemic Low-Dose Doxycycline and Alendronate Administration and Serum Interleukin-1Beta, Osteocalcin, and C-Reactive Protein Levels in Rats Eralp Buduneli,* Nurcan Buduneli,* Saynur Vardar-Şengül,* Levent Kardeşler,* Gül Atilla,* David Lappin,† and Denis F. Kinane‡*Department of Periodontology, School of Dentistry, Ege University, İzmir, Turkey. †Infection and Immunity Group, Glasgow Dental School, University of Glasgow, Glasgow, U.K. ‡Department of Periodontology, School of Dentistry, University of Louisville, Louisville, KY. Correspondence: Dr. Nurcan Buduneli, Department of Periodontology, School of Dentistry, Ege University, 35100 Bornova, İzmir, Turkey. Fax: 90-232-388-03-25; e-mail: nurcan.buduneli@ege.edu.tr. Background: The aim of the present study was to evaluate the effects of systemic administration of low-dose doxycycline and a bisphosphonate, alendronate, on serum levels of interleukin-1β (IL-1β), osteocalcin (OC), and C-reactive protein (CRP) in experimental periodontitis in rats. Methods: Experimental periodontitis was induced by repeated injection of purified lipopolysaccharide (LPS) derived from Escherichia coli endotoxin. Forty-seven adult male Sprague-Dawley rats were divided into five study groups and given LPS, LPS + doxycycline, LPS + alendronate, LPS + doxycycline + alendronate, and saline control. At the end of the 1-week protocol, blood samples were obtained, and the rats were sacrificed. Serum samples were analyzed for IL-1β, OC, and CRP concentrations by enzyme-linked immunosorbent assay (ELISA). The jaws were defleshed, and alveolar bone loss was assessed morphometrically. Data were evaluated statistically by non-parametric tests. Results: Morphometric measurements revealed significantly more bone loss in the LPS group compared to the saline control group (P <0.05). Alendronate revealed slight inhibition on alveolar bone loss either alone or in combination with doxycycline (alveolar bone loss: 0.41 mm in alendronate and combined drug treatment groups versus 0.45 mm in LPS and doxycycline groups). Significantly higher IL-1β levels were observed with alendronate either alone or in combination with doxycycline than in the LPS group (P <0.05). Combined administration of doxycycline and alendronate showed significantly higher levels of OC than all of the other groups (P <0.01). Serum CRP levels did not exhibit significant differences between the study groups. Conclusions: Alendronate either alone or in combination with doxycycline provided slight inhibition on LPS-induced alveolar bone resorption. The significantly increased serum OC level observed in the combined drug treatment group suggests that combined administration of alendronate and doxycycline might increase bone remodeling and thereby inhibit the progression of alveolar bone resorption in rats. KEYWORDS: Alendronate, alveolar bone loss, C-reactive protein, doxycycline, interleukin-1β, osteocalcin Cited byDavid F. Lappin, Bob Eapen, Douglas Robertson, Jenny Young, Penny J. Hodge. (2009) Markers of bone destruction and formation and periodontitis in type 1 diabetes mellitus. Journal of Clinical Periodontology 36:8, 634-641 Online publication date: 1-Sep-2009. CrossRef Z. Metzger, D. Belkin, N. Kariv, M. Dotan, A. Kfir. (2008) Low-dose doxycycline inhibits bone resorption associated with apical periodontitis. International Endodontic Journal 41:4, 303-309 Online publication date: 1-May-2008. CrossRef Leena Palomo, James Liu, Nabil F Bissada. (2007) Skeletal bone diseases impact the periodontium: a review of bisphosphonate therapy. Expert Opinion on Pharmacotherapy 8:3, 309-315 Online publication date: 1-Mar-2007. CrossRef
|
|
|